SAPNA PRADYUMAN PATEL to Protein Kinase Inhibitors
This is a "connection" page, showing publications SAPNA PRADYUMAN PATEL has written about Protein Kinase Inhibitors.
Connection Strength
0.263
-
A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res. 2011 Aug; 21(4):357-63.
Score: 0.128
-
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer. 2020 02 01; 126(3):523-530.
Score: 0.057
-
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
Score: 0.045
-
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
Score: 0.017
-
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors. Clin Cancer Res. 2020 10 01; 26(19):5102-5112.
Score: 0.015